ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Protocol ID
J1S-MC-JV02
Disease (Sub Disease)
Synovial Sarcoma
Diagnosis Stage
Relapsed/refractory
Sponsor
Eli Lilly and Company
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months to 29 Years
International registry ID's
NCT04145700
Back to Registry
Study Title Randomized Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed Recurrent or Refractory Synovial Sarcoma
Protocol ID J1S-MC-JV02
Disease (Sub Disease) Synovial Sarcoma
Diagnosis Stage Relapsed/refractory
Sponsor Eli Lilly and Company
Links https://clinicaltrials.gov/ct2/show/NCT04145700
Trial Status Closed to Recruitment
Trial Open Date 02/08/2021
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Months to 29 Years
International registry ID's NCT04145700

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.